Eyeworld

References: 1. VEVYE (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC; 2024. 2. Cequa (cyclosporine ophthalmic solution) .09% [package insert]. Sun Ophthalmics, LLC; 2024. 3. Restasis (cyclosporine ophthalmic emulsion) 0.05% [package insert]. Allergan, LLC; 2024. 4. Data on file. VEVYE and the VEVYE logo are trademarks of Novaliq GmbH. Trademarks referenced herein are held by their respective owners. Harrow and the Harrow logo are registered trademarks of Harrow IP, LLC. © 2024 Harrow. All Rights Reserved. VYE-00103 02/24 * In pooled Phase 3 studies. ** An open-label, single-arm, extension study INDICATION AND USAGE: VEVYE (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease. IMPORTANT SAFETY INFORMATION Warnings and Precautions • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces. • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE. Adverse Reactions In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA- 1088. For additional information about VEVYE, please see Brief Summary on adjacent page and Full Prescribing Information at vevye.com. VEVYE ® (cyclosporine ophthalmic solution) 0.1% is the first and only water- free cyclosporine dissolved in a semifluorinated alkane (perfluorobutylpentane) approved to treat both the signs and symptoms of dry eye disease. 1-3 In clinical studies, • 56.8% of patients achieved 3 or more grades of improvement in total corneal fluorescein staining at Day 15 *4 • 66.4% of patients showed at least 3 grades of improvement in corneal staining at Day 29 *4 • 99.8% of patients experienced no or mild instillation site pain** 4 • VEVYE provided sustained improvement over 12 months 4 A Different Cyclosporine NOW AVAILABLE! Scan or visit vevye.com to learn more

• Blank Page
• Blank Page (1)